Safety and Effectiveness of Visipaque 320mg-I/ml for Use in Contrast–Enhanced CT Angiography of Arteries of the Heart

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00348608
Recruitment Status : Completed
First Posted : July 4, 2006
Last Update Posted : July 2, 2007
Information provided by:
GE Healthcare

Brief Summary:
CT (computed tomography) angiography (CTA) is an examination similar to a CAT scan that uses x-rays and a contrast medium (also called dye) to visualize blood flow in arteries and veins throughout the body VISIPAQUE™ will be given through a vein in the arm before having the CTA scan of the heart arteries. The pictures it produces of the heart and its blood vessels will be reviewed and compared to those obtained during the catheter-based coronary angiography to see if the CTA shows the same blockages.

Condition or disease Intervention/treatment Phase
Coronary Artery Disease Drug: iodixanol Phase 3

Study Type : Interventional  (Clinical Trial)
Enrollment : 540 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Diagnostic
Study Start Date : June 2006

Resource links provided by the National Library of Medicine

Drug Information available for: Iodixanol
U.S. FDA Resources

Primary Outcome Measures :
  1. To evaluate diagnostic performance and safety of Visipaque-enhanced CTA images for determination of presence or absence of coronary artery obstruction

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Subject is ≥18 years old.
  • Subject must have been referred for an elective coronary angiography for one of several specified conditions.

Exclusion Criteria:

  • The subject has impaired renal function with a serum creatinine level ≥1.7 mg/dL (150 μmol/L). If the institution’s practising guideline(s) regarding the serum creatinine limits for receiving radiologic contrast medium are lower than 1.7 mg/dL (150 μmol/L), the investigator should follow the practising guideline(s) of their institution.
  • Subject has a known allergy to iodinated contrast agent
  • Subject has atrial fibrillation/flutter or any irregular heart rhythm considered to interfere with temporal acquisition of cardiac CT images.
  • The subject’s resting heart rate is 66-100 bpm and β-blocker therapy is contraindicated.
  • Use of nitroglycerin is contraindicated.
  • Subject has had a prior CABG procedure.
  • Subject has a metal cardiac stent in place or artificial heart valve(s).
  • Subject has had a prior pacemaker or internal defibrillator lead implantation. Subject must agree to discontinue metformin day of and for 48 hours after the CTA procedure.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00348608

United States, New Jersey
Princeton, New Jersey, United States, 08540
Sponsors and Collaborators
GE Healthcare
Study Director: Veronica Reichl GE Healthcare Identifier: NCT00348608     History of Changes
Other Study ID Numbers: DXV302
First Posted: July 4, 2006    Key Record Dates
Last Update Posted: July 2, 2007
Last Verified: June 2007

Keywords provided by GE Healthcare:

Additional relevant MeSH terms:
Coronary Artery Disease
Myocardial Ischemia
Coronary Disease
Heart Diseases
Cardiovascular Diseases
Arterial Occlusive Diseases
Vascular Diseases